Ultomiris Stumbles in Pivotal Adult HSCT-TMA Trial, but Paediatric Data Pave a Path to Filing
AZN sits 27% above its 52-week low of $134.9.
Summary
Ultomiris missed its primary endpoint in a Phase III trial for adults with HSCT-TMA, but showed survival benefit in children. Alexion will file for paediatric approval while discussing adult data with regulators.
Key Events · Product Development and Regulatory · AZN
-
Adult HSCT-TMA Trial Misses Primary Endpoint
The ALXN1210-TMA-313 Phase III trial of Ultomiris in adults and adolescents with HSCT-TMA did not achieve statistical significance for event-free survival through 26 weeks versus placebo.
-
Paediatric Trial Shows Survival Benefit
In the ALXN1210-TMA-314 paediatric trial, Ultomiris demonstrated 87.2% overall survival at 26 weeks and 73.4% at 52 weeks, supporting regulatory filings for children with HSCT-TMA.
-
Regulatory Path Forward
Alexion is advancing regulatory filings for Ultomiris in paediatric HSCT-TMA based on the positive paediatric data and real-world evidence. Discussions with health authorities continue for the adult indication.
-
Safety Profile Consistent
The safety profile in both trials was consistent with the known profile of Ultomiris and that seen in patients undergoing HSCT, with no new safety signals.
Analysis · AZN · Life Sciences
A key label expansion for Ultomiris hit a roadblock after the Phase III trial in adults and adolescents with HSCT-TMA missed its primary endpoint of event-free survival. The setback is tempered by clinically meaningful survival benefits in the paediatric trial, prompting Alexion to advance regulatory filings for that population. While the adult indication now faces uncertainty, the near-term paediatric opportunity remains intact. For AstraZeneca, with a $262B market cap, the financial impact is modest, yet the readout marks a significant pipeline moment for the rare disease franchise.
At the time of this filing, AZN was trading at $171.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $262.5B. The 52-week trading range was $134.90 to $212.71. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.